Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Cash & Equivalents (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Cash & Equivalents for 14 consecutive years, with $46.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 29.32% year-over-year to $46.6 million, compared with a TTM value of $46.6 million through Dec 2025, up 29.32%, and an annual FY2025 reading of $46.6 million, up 29.32% over the prior year.
  • Cash & Equivalents was $46.6 million for Q4 2025 at Fate Therapeutics, up from $40.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $133.6 million in Q4 2021 and bottomed at $33.3 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $63.9 million, with a median of $46.7 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents plummeted 82.3% in 2021, then surged 188.72% in 2024.
  • Year by year, Cash & Equivalents stood at $133.6 million in 2021, then crashed by 54.09% to $61.3 million in 2022, then tumbled by 31.73% to $41.9 million in 2023, then dropped by 13.89% to $36.1 million in 2024, then rose by 29.32% to $46.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for FATE at $46.6 million in Q4 2025, $40.6 million in Q3 2025, and $41.2 million in Q2 2025.